O
Olivier Rosmorduc
Researcher at University of Paris
Publications - 145
Citations - 12937
Olivier Rosmorduc is an academic researcher from University of Paris. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 44, co-authored 140 publications receiving 10507 citations. Previous affiliations of Olivier Rosmorduc include Pierre-and-Marie-Curie University & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Thomas Yau,Joong-Won Park,Richard S. Finn,A-L Cheng,Philippe Mathurin,Julien Edeline,Masatoshi Kudo,K.-H. Han,James J. Harding,Philippe Merle,Olivier Rosmorduc,L. Wyrwicz,Eckart Schott,S.P. Choo,Robin Katie Kelley,D. Begic,G. Chen,Jaclyn Neely,Jeffrey Anderson,Bruno Sangro +19 more
TL;DR: Though the primary endpoint of OS did not achieve statistical significance vs SOR, NIVO showed clinically meaningful improvements in OS, ORR, and CR rate as 1L treatment for aHCC and demonstrated a favorable safety profile consistent with previous reports.
Journal ArticleDOI
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu,Olivier Rosmorduc,T.R. Jeffry Evans,Paul Ross,Armando Santoro,Flair José Carrilho,Jordi Bruix,Shukui Qin,Paul J. Thuluvath,Josep M. Llovet,Marie Aude Leberre,Markus Jensen,Gerold Meinhardt,Yoon-Koo Kang +13 more
TL;DR: Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC, and AEs matched the known safety profiles of both agents, but rates of rash/desquamation, anorexia, and diarrhea were higher in the sorafanib/erlotinIB arm, whereas rates of alopecia and hand-foot skin reaction were higherIn the sorAFenib/placebo arm.
Journal ArticleDOI
Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis
Christophe Corpechot,Véronique Barbu,Dominique Wendum,Nils Kinnman,Colette Rey,Raoul Poupon,Chantal Housset,Olivier Rosmorduc +7 more
TL;DR: It is shown that in DEN‐treated rats, although the progression of liver fibrosis is associated with hepatocellular hypoxia and angiogenesis, VEGF and Flt‐1 expressions in the liver are increased and correlated with the density of microvessels.